About Nacuity Pharmaceuticals
Nacuity Pharmaceuticals is a private company based in Fort Worth, Texas. It has reported $31,219,350 raised in four offerings on Form D since December 2016. Its chief executive is Halden Conner.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Dec 11, 2025 | Dec 30, 2025 | $8,393,350of $30.0M target | 98 | $85,646 | Equity, Debt, Options, Securities on exercise, Convertible Promissory Notes convertible into preferred stock or common stock, Common Stock Purchase Warrants, Common Stock issued for Warrant ConversionRule 506(b) | Form D ↗ |
| Mar 16, 2021 | Mar 30, 2021amended Jan 3, 2022 | $11,626,000of $17.4M target | 144 | $80,736 | Equity, Options, Securities on exercise, Units comprised of Convertible Preferred Shares plus Common Stock Purchase Warrants; Common Stock issued for Warrant conversion; Convertible Preferred Shares issued for exchange of Common StockRule 506(b) | Form D/A ↗1 earlier filing |
| Jun 15, 2017 | Jun 27, 2017amended Jul 20, 2017 | $9,227,000of $10.0M target | 125 | $73,816 | Equity, Options, Units comprised of Convertible Preferred Shares plus Common Stock Purchase WarrantsRule 506(b) | Form D/A ↗1 earlier filing |
| Nov 8, 2016 | Dec 8, 2016 | $1,973,000of $2.5M target | 46 | $42,891 | EquityRule 506(b) | Form D ↗ |
| Total, four offerings | $31,219,350 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Nacuity Pharmaceuticals's Form D filed Dec 30, 2025.
Earlier filings also listed Robin Steel (director, last listed Jan 2022), Robert Ruffolo (director, last listed Jan 2022), William Conner (president and chief executive officer, director, last listed Jul 2017), Sanford Hillsberg (director, last listed Jul 2017), Richard Chin, M.D. (director, last listed Jul 2017), Isaac Blech (director, last listed Jul 2017), G. Wall, Ph.D. (vice president of research and development, last listed Jul 2017) and Dr. Gerald Cagle (director, last listed Jul 2017).